Clearmind Medicine Inc. Rises 33.84% on CMND-100 Trial Progress

Clearmind Medicine Inc. saw a significant increase of 33.84% in pre-market trading, with the stock price reaching new heights. The rise follows the successful recruitment of the first patient for the CMND-100 clinical trial at the Tel Aviv Sourasky Medical Center, marking a crucial milestone in the company's Phase I/IIa trial for treating alcohol use disorder.

This trial is FDA-approved and aims to enhance Clearmind's competitiveness in the psychedelic medicine sector. The involvement of prestigious institutions like Yale and Johns Hopkins in the trial network further strengthens the company's position in global clinical research.

The initial results from the trial have shown excellent safety and adherence, with no serious adverse events reported. This positive outcome not only supports the ongoing development of CMND-100 but also positions it as a potential breakthrough therapy for alcohol use disorder.